IRAK

IRAK4-IN-22 (compound 18) is an orally effective and selective potent IRAK4 inhibitor with IC50 values of 3 and 17 nM for IRAK4 and TAK1, respectively. IRAK4-IN-21 can effectively inhibit the production of IL-23 (IC50=0.10 μM), which can be used in research on autoimmune diseases such as psoriasis vulgaris and psoriatic arthritis.

IRAK4-IN-20 (Compound BAY-1834845) is an orally active IRAK4 inhibitor with an IC50 of 3.55 nM.

GLPG2534 is an orally active and selective IRAK4 inhibitor, with IC50 values of 6.4 nM and 3.5 nM for human and mouse IRAK4.

KTX-582 is a potent IRAK4 degrader with DC50 values of 4 nM and 5 nM for IRAK4 and Ikaros, respectively.

KTX-951 is a PROTAC targeting IRAK4 degradation (DC50=18 nM).

Larotinib is a potent broad-spectrum and orally active tyrosine kinase inhibitor (TKI) with EGFR as the main target with an IC50 of 0.6 nM.

KME-2780 is a potent and selective dual IRAK1 and IRAK4 inhibitor and can be used for research of dysregulation of innate immune signaling and hematologic malignancies.

IRAK1/4/pan-FLT3 Kinase-IN-1 hydrochloride is an orally active, potent and selective IRAK / pan-FLT3 kinase inhibitor with IC 50 s of 5 nM, 0.6 nM and <0.5 nM against IRAK1, IRAK4 and FLT3, respectively.

KT-474 (KYM-001; PROTAC IRAK4 degrader-7) hydrochloride is an orally active PROTAC IRAK4 degrader with anti-tumor effects.

APH02174 hemiformic is a highly selective and orally active IRAK4 PROTAC degrader with the DC 50 of 4.01 nM in THP-1 cells.

PSP-0119 is a highly efficient and effective PROTAC degrader targeting IRAK4 ( IC 50 = 2.83 nM).

Ginsenoside Rb1 is a natural active ingredient extracted from ginseng that can modulate the activity of multiple signaling pathways.